BTLA-Expressing Memory B Cells Mediate Belimumab-Induced Improvement in Systemic Lupus Erythematosus

Key Points

• Belimumab treatment leads to a significant improvement in disease activity in systemic lupus erythematosus.
• Participants treated with belimumab showed enhanced BTLA-expressing memory B cells associated with disease improvement.
• Analysis of immune response involved assessment of specific biomarkers and cytokine levels affecting outcomes.
• Findings suggest that targeting memory B cells may increase the effectiveness of treatments for lupus.

Abstract